• A recent death in the UK has been linked to tirzepatide (Mounjaro), raising concerns about the safety of GLP-1 receptor agonists.
• Online pharmacies selling weight-loss medications face increased regulatory scrutiny due to breaches in safety standards.
• Clinical trials show GLP-1 drugs like Wegovy reduce cardiovascular events, but side effects and individual risks must be considered.
• Experts caution against viewing GLP-1 drugs as a "silver bullet" for obesity, emphasizing the need for careful patient selection and monitoring.